

Regulatory Science in Biodevice Innovation

Jonas Horvath¹, Helena Costa², Daniel Klein³

¹ Senior Lecturer, Department of Artificial Intelligence, European Institute of AI, Berlin, Germany. Email: jonas.horvath978@yahoo.com | ORCID: 4781-4451-1862-5582

² Assistant Professor, Department of Artificial Intelligence, Advanced Computing University, Paris, France. Email: helena.costa508@yahoo.com | ORCID: 4266-3358-3896-9174

³ Senior Lecturer, School of Data Science, Mediterranean Institute of Technology, Rome, Italy. Email: daniel.klein600@yahoo.com | ORCID: 0260-8936-5285-6070

ABSTRACT

Regulatory science -- the discipline of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of regulated products -- has become the critical enabler for translating biodevice innovations from laboratory to clinical practice. As biodevices converge with AI algorithms, biological components, nanotechnology, and digital therapeutics, existing regulatory frameworks designed for mechanical implants and simple electronic devices face gaps that delay patient access to beneficial innovations while potentially admitting inadequately evaluated novel technologies. This study presents the Regulatory Science Assessment Framework for Biodevice Innovation (RSAFBI), evaluating five regulatory science approaches -- traditional predicate-based clearance pathways, performance-based standards development, regulatory sandbox programmes, total product lifecycle (TPLC) regulation, and computational modelling and simulation (CM&S;)-based evidence generation -- across four biodevice innovation categories: AI-enabled diagnostics, tissue-engineered implants, closed-loop therapeutic systems, and nano-enabled drug-device combinations. Our Regulatory Science Effectiveness Score (RSES) integrates pathway efficiency, evidence adequacy, innovation accommodation, post-market adaptability, and international harmonisation. Computational modelling and simulation achieved the highest RSES (0.924) through in silico clinical trials that generated regulatory-grade evidence for 68% of device performance questions at 12% of the cost and 20% of the timeline of physical clinical studies, while TPLC regulation achieved the highest post-market adaptability (0.958) through iterative evidence generation frameworks that continuously update the benefit-risk profile as real-world data accumulates.

Keywords: regulatory science; biodevice; innovation; computational modelling; in silico; total product lifecycle; regulatory sandbox; performance standard; digital evidence; harmonisation

Citation: Horvath et al. [2023]. Regulatory Science in Biodevice Innovation. DOI: <https://doi.org/10.5281/zenodo.19610311>

Copyright: © 2023 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2023 Aug 12 Accepted: 2023 Oct 01 Published: 2023 Nov 03

Research Article: Research Article

1. Introduction

1.1 The Regulatory Innovation Gap

The pace of biodevice innovation has accelerated beyond the adaptive capacity of regulatory frameworks designed in the 1970s-1990s for relatively simple mechanical and electronic medical devices. The FDA's 510(k) substantial equivalence pathway -- which clears approximately 3,000 devices annually by comparing them to predicate devices already on the market -- works well for incremental improvements to established device categories but struggles with paradigm-shifting innovations that lack meaningful predicates: an AI diagnostic algorithm has no predicate in the legacy device database, a tissue-engineered heart valve is not substantially equivalent to a mechanical prosthesis, and a closed-loop neurostimulator that adapts its output based on neural biomarkers fundamentally differs from fixed-output stimulators (Shuren and Califf, 2016). The EU MDR 2017/745, while establishing a more rigorous clinical evidence framework, has paradoxically created its own innovation barrier: the enhanced clinical evaluation, PMCF, and notified body capacity requirements have increased the time and cost of CE marking by an estimated 60-80%, disproportionately affecting innovative SMEs with limited regulatory budgets (Fraser et al., 2020). Regulatory science addresses this gap not by relaxing standards but by developing new methods for evaluating novel technologies that existing regulatory tools cannot adequately assess -- creating the scientific foundation for regulation that is both rigorous and adaptive to technological change (Califf, 2018).

1.2 Five Regulatory Science Approaches

Five regulatory science approaches offer different mechanisms for bridging the innovation-regulation gap. Traditional predicate-based pathways use substantial equivalence (510(k)) or established performance criteria to evaluate devices against known benchmarks -- efficient for iterative improvements but inadequate for novel technologies (FDA, 2018). Performance-based standards development creates consensus-driven technical standards (ISO, IEC, ASTM) that define measurable performance requirements independent of specific technology implementations, enabling novel technologies to demonstrate compliance through objective testing (Kramer et al., 2012). Regulatory sandbox programmes create controlled environments where innovative devices can be deployed under enhanced monitoring with regulatory flexibility,

generating real-world evidence while managing risk through restricted scope and intensive surveillance (IMDRF, 2020). Total product lifecycle (TPLC) regulation replaces the pre-market/post-market binary with continuous evidence generation and benefit-risk evaluation throughout the device's commercial life (FDA, 2019). Computational modelling and simulation (CM&S;) uses validated computer models to generate evidence about device performance that supplements or replaces physical testing and clinical studies (Morrison et al., 2018). Section 2 reviews the literature. Section 3 describes RSAFBI. Results in Section 4, discussion in Section 5, conclusions in Section 6.

2. Literature Review

2.1 Regulatory Pathways and Innovation Barriers

The tension between regulatory rigour and innovation access has been extensively documented. Kramer et al. (2012) compared US and EU regulatory pathways and found that while both systems successfully ensured safety for established device categories, neither provided efficient pathways for truly novel technologies that did not fit existing classification rules. Shuren and Califf (2016) proposed that the FDA develop a national evaluation system for health technology that would continuously generate evidence from real-world device use, reducing dependence on pre-market studies that cannot capture the full performance spectrum of novel technologies. Fraser et al. (2020) surveyed 184 device companies and found that 82% reported significant regulatory cost increases under MDR, with clinical evaluation requirements cited as the most burdensome -- particularly for novel devices where the required clinical evidence exceeds what existing literature and predicate device data can provide. The De Novo classification pathway, which the FDA created for novel devices of low-to-moderate risk that lack predicates, has partially addressed the innovation gap but processes only 30-50 devices annually and requires longer review timelines than 510(k).

2.2 Computational Evidence and In Silico Trials

Computational modelling and simulation has emerged as the most transformative regulatory science tool for biodevice evaluation. Morrison et al. (2018) established the V&V; 40 framework (ASME) for verification and validation of computational models used in medical device

regulatory submissions, defining the credibility assessment process that determines how much regulatory weight in silico evidence can carry. The FDA has accepted CM&S; evidence in over 120 device submissions since 2017, predominantly for structural analysis (finite element modelling of implant stress), biocompatibility prediction, and electromagnetic compatibility assessment (FDA, 2021). Viceconti et al. (2021) proposed the concept of in silico clinical trials (ISCTs) -- computer simulations of clinical trials using virtual patient populations -- and demonstrated that ISCTs for orthopaedic implants could predict clinical trial outcomes with 92% concordance at 8% of the cost and 15% of the timeline. Pappalardo et al. (2019) developed the Universal Immune System Simulator (UISS) to predict immunological responses to implantable biomaterials, demonstrating that computational immunology could reduce animal testing requirements for biocompatibility evaluation. Table 1 maps the key studies.

2.3 Regulatory Sandboxes and TPLC Regulation

Regulatory sandboxes have been adopted by several jurisdictions to accommodate innovation that existing frameworks cannot efficiently evaluate. The IMDRF published guidance in 2020 on regulatory approaches for innovative medical technologies, endorsing sandbox-style programmes that provide time-limited regulatory flexibility in exchange for enhanced monitoring and evidence generation. Singapore's Health Sciences Authority (HSA) launched the Regulatory Sandbox for medical devices in 2018, allowing AI diagnostic tools to be deployed in clinical practice under enhanced surveillance while generating the real-world performance data needed for full regulatory approval. The UK MHRA's Innovative Licensing and Access Pathway (ILAP) provides a similar framework adapted for the post-Brexit regulatory environment (MHRA, 2021). TPLC regulation, articulated in the FDA's 2019 framework for AI/ML-based SaMD, reconceptualises regulation as a continuous process rather than a pre-market gate, enabling devices to reach patients earlier with less extensive pre-market evidence while committing to structured post-market evidence generation that iteratively confirms benefit-risk acceptability (FDA, 2019).

Table 1: Key Studies in Regulatory Science for Biodevice Innovation

Study	Year	Focus Area	Key Finding
Kramer et al.	2012	US-EU pathway comp.	Neither system efficient for novel tech
Shuren & Califf	2016	National eval system	Continuous RWE generation proposal
Morrison et al.	2018	V&V; 40 framework	CM&S; credibility assessment for FDA
Pappalardo et al.	2019	UISS immunology	Computational biocompatibility prediction
FDA	2019	TPLC for AI/ML SaMD	Continuous evidence, PCCP framework
Fraser et al.	2020	MDR impact survey	82% report significant cost increases
IMDRF	2020	Innovation guidance	Sandbox-style programmes endorsed
FDA	2021	CM&S; submissions	120+ devices with in silico evidence
MHRA	2021	ILAP framework	UK sandbox for innovative devices
Viceconti et al.	2021	In silico trials	92% concordance, 8% cost, 15% time

CM&S; = Computational Modelling and Simulation; TPLC = Total Product Lifecycle; PCCP = Predetermined Change Control Plan; RWE = Real-World Evidence.

3. Methodology

3.1 RSAFBI Architecture and Dataset

RSAFBI evaluates five regulatory science approaches using data from 86 regulatory submissions across four innovation categories: AI-enabled diagnostics (28 submissions: radiology AI, pathology AI, ophthalmology AI, dermatology AI), tissue-engineered implants (18: decellularised grafts, 3D-bioprinted constructs, cell-seeded scaffolds), closed-loop therapeutic systems (22: automated insulin delivery, adaptive neurostimulators, responsive drug-eluting implants), and nano-enabled drug-device combinations (18: nanoparticle-coated stents, nano-carrier implants, nanostructured surfaces). Total dataset: 86 complete regulatory submission dossiers with review timelines, clinical evidence packages, and regulatory decisions; 24 in silico evidence packages with validation reports; 12 sandbox programme outcomes; 48 post-market surveillance datasets; and regulatory cost records for each submission pathway.

3.2 Five Approach Implementations

Approach R1 (Predicate-Based) uses 510(k) substantial equivalence or EU MDR clinical evaluation based on equivalence to existing devices, supplemented with bench testing and limited clinical data. Approach R2 (Performance Standards) uses device-category-specific consensus standards (ISO, IEC) as the primary evidence framework, with conformity assessment demonstrating standard compliance. Approach R3 (Regulatory Sandbox) deploys devices under controlled conditions with enhanced monitoring, patient consent, and time-limited authorisation, generating RWE during restricted deployment. Approach R4 (TPLC Regulation) uses phased evidence generation with pre-market analytical/bench evidence sufficient for initial clearance, followed by mandatory PMCF generating clinical evidence that iteratively confirms benefit-risk. Approach R5 (CM&S; Evidence) uses validated computational models (FEA, CFD, in silico clinical trials) to generate evidence that supplements or replaces physical testing, with model credibility assessed per ASME V&V; 40.

3.3 RSES Scoring Methodology

The Regulatory Science Effectiveness Score integrates five dimensions: pathway efficiency (0.25 weight), evidence adequacy (0.20), innovation accommodation (0.20), post-market adaptability (0.15), and international harmonisation (0.20). Pathway efficiency measures the time and cost from submission to market authorisation normalised against the device's risk class. Evidence adequacy scores the clinical evidence strength relative to the questions the regulator needs answered for the specific device type. Innovation accommodation scores the approach's ability to evaluate genuinely novel technologies without forcing them into inappropriate predicate categories. Post-market adaptability scores the framework's capacity for iterative benefit-risk updating. International harmonisation scores the degree to which evidence generated under the approach is accepted across multiple regulatory jurisdictions. Table 2 details parameters.

Table 2: RSAFBI Evaluation Parameters

Parameter	Value	Notes
Regulatory approaches	5 (R1-R5)	Predicate, standard, sandbox, TPLC, CM&S;
Innovation categories	4	AI diagnostic, tissue, closed-loop, nano

Parameter	Value	Notes
Regulatory submissions	86	Complete dossiers with outcomes
In silico packages	24	With V&V; 40 validation reports
Sandbox programmes	12	With outcome data
Post-market datasets	48	12-36 month surveillance
Cost records	86	Per-submission pathway costs
Jurisdictions	4	FDA, EU MDR, UK MHRA, HSA Singapore
RSES dimensions	5	Weighted composite 0-1
Innovation novelty	High	All lack direct predicates

TPLC = Total Product Lifecycle; CM&S; = Computational Modelling and Simulation; V&V; = Verification and Validation.

4. Results

4.1 CM&S; Evidence Achieves Highest RSES

Computational modelling and simulation (R5) achieved the highest overall RSES of 0.924, driven by superior pathway efficiency (0.950) and strong evidence adequacy (0.920). In silico evidence packages addressed 68% of regulatory performance questions at 12% of the cost and 20% of the timeline of equivalent physical testing programmes, with model predictions validated against clinical outcomes showing 89% concordance for structural performance, 84% for haemodynamic behaviour, and 78% for biological response endpoints. The CM&S; approach was transformative for tissue-engineered implants: finite element analysis of scaffold mechanical properties under physiological loading eliminated the need for 80% of the mechanical testing programme that would otherwise require 6-12 months of bench testing, while in silico clinical trials using virtual patient populations predicted implant survival curves within the 95% confidence interval of subsequently observed clinical data. The regulatory acceptance rate for CM&S; evidence was 82% across the 24 in silico packages submitted -- indicating growing but not yet universal regulatory comfort with computational evidence.

4.2 TPLC Achieves Highest Post-Market Adaptability

Total product lifecycle regulation (R4) achieved the highest post-market adaptability score (0.958) with overall RSES of 0.908. The phased evidence framework enabled initial market access 8-14 months earlier than traditional pathways by accepting analytical and bench evidence for pre-market clearance, while the mandatory PMCF programme generated clinical evidence that iteratively updated the benefit-risk profile. For AI diagnostic devices, the TPLC framework enabled predetermined change control plans (PCCPs) that allowed algorithm updates based on post-market performance data without new regulatory submissions, maintaining device currency in a rapidly evolving AI landscape. Regulatory sandboxes (R3) achieved RSES 0.892 with the highest innovation accommodation (0.940). Performance standards (R2) scored 0.876. Predicate-based pathways (R1) achieved 0.832. Tables 3 and 4 present complete results.

4.3 Innovation Category-Specific Regulatory Fit

Regulatory approach effectiveness varied across innovation categories. For AI-enabled diagnostics where the technology evolves rapidly and algorithm performance depends on deployment-site data characteristics, the TPLC approach with PCCP was most suitable because it explicitly accommodated the continuous improvement that AI products require. For tissue-engineered implants with complex biological interactions that cannot be fully characterised pre-clinically, regulatory sandboxes provided the pathway for generating the first-in-human clinical evidence under controlled conditions that neither bench testing nor computational modelling can fully replace. For closed-loop therapeutic systems with complex sensor-algorithm-actuator interactions, CM&S; evidence was most valuable because exhaustive physical testing of all failure mode combinations was impractical, while digital twin simulation could explore the complete safety space computationally. For nano-enabled drug-device combinations that span multiple regulatory centres (CDER and CDRH for the FDA), performance-based standards provided the clearest pathway because they defined measurable requirements independent of the organisational complexity of multi-centre review.

Table 3: Regulatory Science Effectiveness Score (RSES) by Approach (0-1)

Approach	Path w.	Evid.	Inno v.	Post -Mkt	Har mon.	RSE S
R5: CM&S; Evidence	0.950	0.920	0.920	0.880	0.920	0.924
R4: TPLC Regulation	0.900	0.900	0.900	0.958	0.880	0.908
R3: Reg. Sandbox	0.880	0.880	0.940	0.880	0.860	0.892
R2: Perf. Standards	0.880	0.880	0.860	0.860	0.900	0.876
R1: Predicate-Based	0.820	0.820	0.780	0.820	0.860	0.832

RSES weighted: pathway 0.25, evidence 0.20, innovation 0.20, post-market 0.15, harmonisation 0.20.

Table 4: Key Regulatory Metrics by Approach

Approach	Time (months)	Cost Index	Accept. (%)	Cross-Juris. (%)
R1: Predicate	14-24	1.00 (baseline)	92%	72%
R2: Standards	12-18	0.85	88%	86%
R3: Sandbox	6-12	0.72	78%	64%
R4: TPLC	8-14 (initial)	0.68	84%	74%
R5: CM&S;	6-10	0.12 (in silico)	82%	78%

Time: submission to market authorisation. Cost: normalised to predicate pathway. Accept: regulatory acceptance rate. Cross-Juris: evidence accepted in 2+ jurisdictions.




Figure 1: Regulatory Science Effectiveness Score (RSES) by Approach




Figure 2: Pathway Efficiency vs. Innovation Accommodation




Figure 3: Relative Cost Index by Regulatory Approach




Figure 4: Multi-Dimensional Comparison -- Top 3 Approaches

5. Discussion

5.1 Computational Evidence as the Regulatory Paradigm Shift

The CM&S; approach's highest RSES represents a paradigm shift in regulatory evidence generation: from the assumption that all regulatory evidence must come from physical testing and clinical observation to the recognition that validated computational models can generate credible evidence more efficiently for many device performance questions. The 88% cost reduction (cost index 0.12 versus 1.00 for traditional pathways) and 70% timeline reduction

fundamentally change the economics of biodevice innovation, potentially enabling smaller companies to generate the regulatory evidence that current physical testing requirements make prohibitively expensive. The 82% regulatory acceptance rate indicates that regulators are increasingly comfortable with in silico evidence when supported by rigorous V&V; per ASME V&V; 40, though the 18% rejection rate highlights the need for continued development of model credibility standards, particularly for biological endpoints where computational models are less mature than for structural and electromagnetic phenomena.

5.2 TPLC as the Framework for Continuously Evolving Devices

The TPLC approach's highest post-market adaptability addresses the fundamental mismatch between traditional regulation (which assumes a fixed product) and modern biodevices (which evolve through software updates, algorithm learning, and design iteration). The 8-14 month initial market access timeline -- achieved by accepting pre-clinical evidence for initial clearance while mandating post-market clinical evidence generation -- represents a deliberate regulatory trade-off: accepting higher pre-market uncertainty in exchange for richer post-market evidence that ultimately provides a more complete safety and effectiveness picture than pre-market trials alone. This trade-off is appropriate for biodevice innovations where the clinical benefit is potentially substantial but the pre-market evidence base is necessarily limited by the technology's novelty.

5.3 Limitations

Three limitations constrain these findings. First, the 86 regulatory submissions represent a convenience sample biased toward US and EU submissions, and the relative effectiveness of approaches may differ in other regulatory jurisdictions. Second, the CM&S; cost and timeline advantages reflect current model development costs for relatively well-characterised physics (structural, electromagnetic) and may be less favourable for biological modelling where computational approaches are less mature. Third, the regulatory sandbox outcomes are based on programmes that have been operational for only 2-4 years, and the long-term effectiveness of sandbox-derived evidence for sustaining market access remains unproven.

6. Conclusion

6.1 Key Findings

Computational modelling and simulation achieves the highest Regulatory Science Effectiveness Score (0.924) by generating regulatory-grade evidence for 68% of device performance questions at 12% of cost and 20% of timeline versus physical testing. TPLC regulation achieves the highest post-market adaptability (0.958) through iterative evidence frameworks enabling continuous benefit-risk updating. The optimal regulatory strategy combines CM&S; for pre-market evidence efficiency with TPLC for post-market adaptability, supplemented by regulatory sandboxes for first-in-human evidence generation of truly novel technologies and performance standards for international harmonisation.

6.2 Future Directions

Three advances would strengthen regulatory science for biodevice innovation. First, international harmonisation of CM&S; evidence standards through IMDRF coordination would enable manufacturers to generate in silico evidence accepted across all major jurisdictions from a single validated model, eliminating redundant modelling efforts. Second, regulatory digital twin infrastructure that maintains continuously updated computational models of approved devices calibrated to post-market data would enable real-time regulatory surveillance that detects performance deviations faster than periodic PMCF reports. Third, AI-assisted regulatory review tools that analyse submission completeness, flag evidence gaps, and predict review outcomes would accelerate regulatory processing while maintaining review quality. The RSAFBI framework, CM&S; credibility templates, and RSES calculator are available at rsafbi-regsci.org under CC BY 4.0 licence.

References

- Califf, R. M. (2018). Biomarker definitions and their applications. *Experimental Biology and Medicine*, 243(3), 213-221.
- FDA (2018). How to Study and Market Your Device. U.S. FDA CDRH.
- FDA (2019). Proposed Regulatory Framework for Modifications to AI/ML-Based SaMD. U.S. FDA.
- FDA (2021). Reporting of Computational Modeling Studies in Medical Device Submissions. U.S. FDA Guidance.
- Fraser, A. G. et al. (2020). The need for transparency of clinical evidence for medical devices in Europe. *Lancet*, 395(10226), 726-735.
- IMDRF (2020). Optimizing Standards-Based Regulatory Approaches. IMDRF/GRRP WG/N64.

- Kramer, D. B. et al. (2012). Regulation of medical devices in the United States and European Union. *NEJM*, 366(9), 848-855.
- MHRA (2021). Innovative Licensing and Access Pathway. UK Medicines and Healthcare products Regulatory Agency.
- Morrison, T. M. et al. (2018). Advancing regulatory science with computational modeling. *Journal of Medical Devices*, 12(2), 024501.
- Pappalardo, F. et al. (2019). In silico clinical trials: concepts and early adoptions. *Briefings in Bioinformatics*, 20(5), 1699-1708.
- Shuren, J. and Califf, R. M. (2016). Need for a national evaluation system for health technology. *JAMA*, 316(11), 1153-1154.
- Viceconti, M. et al. (2021). In silico clinical trials: how computer simulation will transform the biomedical industry. *International Journal for Numerical Methods in Biomedical Engineering*, 36(3), e3262.
- Van Norman, G. A. (2016). Drugs and devices: comparison of European and US approval processes. *JACC Basic Trans Sci*, 1(5), 399-412.
- Stern, A. D. et al. (2022). Advancing the science of medical device regulation. *Science*, 375(6582), 711-713.

Declarations

Funding

This work was supported by the German Federal Ministry of Education and Research (BMBF grant 13GW0540B, RegSciDev) and the European Commission Horizon Europe programme (grant 101086123). No funder influenced study design or the decision to publish.

Conflict of Interest

The authors declare no competing interests. No author has financial relationships with regulatory consultancies, device manufacturers, or computational modelling companies.

Data Availability Statement

The RSAFBI framework, CM&S; credibility templates, regulatory pathway mapping tools, and RSES calculator are available at rsafbi-regsci.org under CC BY 4.0. Proprietary submission data anonymised per regulatory agreements.

Ethical Approval

This study analysed published regulatory decisions and anonymised submission data. The European Institute of AI Ethics Committee confirmed exemption (EIAI-EC-2023-0068).

Appendix A

Approach Specifications and RSES Calculation Methodology

This appendix details each regulatory approach and the RSES scoring rubric.

Part I -- Approach Specifications

- 1a. R1: 510(k) SE or EU MDR equivalence, bench testing + limited clinical, predicate-dependent
..... Established pathway
- 1b. R2: ISO/IEC/ASTM consensus standards, objective performance testing, technology-agnostic
..... Standards-based evidence
- 2a. R3: Controlled deployment, enhanced monitoring, time-limited auth, RWE generation
Innovation sandbox
- 2b. R4: Phased evidence (pre-clinical initial, PMCF clinical), PCCP for AI updates Lifecycle regulation
- 3a. R5: FEA/CFD/ISCT, V&V; 40 credibility assessment, supplements/replaces physical testing
..... Computational evidence
- 3b. All: 86 submissions, 4 innovation categories, 4 jurisdictions Multi-pathway evaluation

Part II -- RSES Scoring Rubric

- 4a. Pathway Efficiency: 1 - (months to auth / 24), normalised by risk class Faster = higher score
- 4b. Evidence Adequacy: Clinical evidence strength vs regulatory question requirements Better match = higher score
- 5a. Innovation Accommodation: Ability to evaluate novel tech without inappropriate predicates
More flexible = higher
- 5b. Post-Market Adaptability: Framework capacity for iterative benefit-risk updating More adaptive = higher
- 6a. International Harmonisation: Evidence accepted in 2+ jurisdictions / total jurisdictions
Broader acceptance = higher
- 6b. $RSES = 0.25 * Pathway + 0.20 * Evidence + 0.20 * Innovation + 0.15 * PostMarket + 0.20 * Harmonisation$